Third Generation Sequencing Market, By Type of Technology (Single-molecule real-time (SMRT) sequencing, Nanopore sequencing, Synthetic long-read sequencing), By Component (Products and Services), By Application: (Genome sequencing, Epigenetics, Transcript

Third Generation Sequencing Market, By Type of Technology (Single-molecule real-time (SMRT) sequencing, Nanopore sequencing, Synthetic long-read sequencing), By Component (Products and Services), By Application: (Genome sequencing, Epigenetics, Transcriptomics, Metagenomics, Others), By End-User (Biopharmaceutical companies, Hospitals and clinics, Contract research organizations (CROs), Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East)

Third-generation sequencing (also known as long-read sequencing) is a class of DNA sequencing methods. Third-generation sequencing works by reading nucleotide sequences at a single molecule level, which is capable of producing substantially much longer reads than the current methods. It has the ability to generate longer reads than second-generation sequencing, also known as next-generation sequencing. Moreover, third-generation sequencing has emerged as the ‘gold-standard’ technology for cDNA sequencing.

Market Dynamics:

Rising prevalence of chronic and infectious diseases, increasing applications in clinical diagnosis, growing applications of genomics, rise in focus on drug discovery and development, and growing efficiency compared to traditional technologies are major factors expected to propel growth of the global third generation sequencing market.

For instance, with the rise in burden of chronic disease, the usage or demand for third-generation sequencing technology-based devices is also increasing with a rapid pace. TGS technologies can be utilized in studying gene expression of chronic diseases as it help in understanding their molecular mechanisms. According to the World Health Organization (WHO), September 2023 report, non-communicable diseases (NCDs) kill 41 million individuals each year, equivalent to 74% of all deaths worldwide. Cardiovascular diseases account for most NCD deaths, or 17.9 million people annually, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million).

Moreover, according to the Centers for Disease Control and Prevention (CDC), chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the U.S.

Key features of the study:

• This report provides in-depth analysis of the global third generation sequencing market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global third generation sequencing market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include PacBio , Oxford Nanopore Technologies, Ltd., BGI Genomics Co., Ltd., F. Hoffmann-La Roche AG, Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Agilent Technologies, Inc., GenapSys Inc., Loop Genomics, Nabsys, Inc., Genia Technologies, Inc., Stratos Genomics, Inc., GATC Biotech AG, and Phase Genomics, Inc., among others
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global third generation sequencing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global third generation sequencing market.

Detailed Segmentation:

• By Technology:
• Single-Molecule Real-Time (SMRT) Sequencing
• Nanopore Sequencing
• Synthetic long-read sequencing
• By Component:
• Products
• Instruments
• Reagents and consumables
• Services
• By Application:
• Genome Sequencing
• Epigenetics
• Transcriptomics
• Metagenomics
• Others
• By End-user:
• Biopharmaceutical companies
• Hospitals and clinics
• Contract research organizations (CROs)
• Others (Academic and research institutes)
• By Geography:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa
• Company Profiles:
• PacBio
• Oxford Nanopore Technologies, Ltd.
• BGI Genomics Co., Ltd.
• F.Hoffmann-La Roche AG
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Agilent Technologies, Inc.
• GenapSys Inc.
• Loop Genomics
• Nabsys, Inc.
• Genia Technologies, Inc.
• Stratos Genomics, Inc.
• GATC Biotech AG
• Phase Genomics, Inc.